Related Experiment Video
Updated: Jul 15, 2026
10:47
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Targeted therapy in nuclear medicine--current status and future prospects
W J G Oyen1, L Bodei, F Giammarile
1Therapy Committee of the European Association of Nuclear Medicine, Hollandstrasse 14 / Mezzanine, A-1020 Vienna, Austria. w.oyen@nucmed.umcn.nl
Summary
Targeted radionuclide therapy has advanced significantly, offering new options for thyroid cancer, lymphoma, and solid tumors using radiolabeled compounds. These targeted therapies, including antibodies and small molecules, are improving treatment for various cancers.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Targeted radionuclide therapy has seen significant advancements.
- New developments include radioiodine treatment, radiolabeled monoclonal antibodies (mAbs), and small receptor-specific molecules.
Purpose of the Study:
- To review recent developments in targeted therapies using radiolabeled compounds.
- To discuss the application of these therapies in various cancers, including thyroid cancer, lymphoma, and solid tumors.
- To explore locoregional treatment for liver malignancies.
Main Methods:
- Review of current literature on targeted radionuclide therapy.
- Discussion of specific radiolabeled agents like radioiodine, mAbs, meta-iodobenzylguanidine, peptides, and somatostatin derivatives.
- Analysis of treatment protocols and outcomes for different cancer types.
Main Results:
- Radioiodine treatment protocols for thyroid cancer have been updated with recombinant human thyroid-stimulating hormone and retinoids.
- Radiolabeled mAbs offer new options for lymphoma but are challenging for solid tumors.
- Radiolabeled small molecules and peptides enable high-dose radiation delivery to disseminated tumors, with somatostatin derivatives as a model.
- Locoregional radiopharmaceutical treatment is effective for inoperable liver cancers and can be used in neoadjuvant/adjuvant settings.
Conclusions:
- Targeted radionuclide therapy has significantly advanced, with new clinical modalities introduced.
- Combining therapeutic radiopharmaceuticals with other treatment modalities is an area of increasing exploration.
- These developments offer improved treatment strategies for various malignancies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
Fundamental Principles of PET
01:29Positron Emission Tomography
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
01:28Isotopes and Radioisotopes
In the early 1900s, English chemist Frederick Soddy realized that an element could have atoms with different masses that were chemically indistinguishable. These different types are called isotopes — atoms of the same element that differ in mass. Isotopes differ in mass because they have different numbers of neutrons but are chemically identical because they have the same number of protons. Soddy was awarded the Nobel Prize in Chemistry in 1921 for this discovery.
An isotope containing more...
An isotope containing more...
03:20Nuclear Transmutation
Nuclear transmutation is the conversion of one nuclide into another. It can occur by the radioactive decay of a nucleus, or the reaction of a nucleus with another particle. The first manmade nucleus was produced in Ernest Rutherford’s laboratory in 1919 by a transmutation reaction, the bombardment of one type of nuclei with other nuclei or with neutrons. Rutherford bombarded nitrogen-14 atoms with high-speed α particles from a natural radioactive isotope of radium and observed protons being...